Literature DB >> 12189169

Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome.

Marie-Thérèse Bihoreau1, Natalia Megel, Joanna H Brown, Bettina Kränzlin, Laurence Crombez, Yulia Tychinskaya, John Broxholme, Susanne Kratz, Volker Bergmann, Sigrid Hoffman, Dominique Gauguier, Norbert Gretz.   

Abstract

The genetic analysis of rodent disease models provides a powerful tool to investigate how modifier loci cause variation in the phenotypic expression of a disease. In order to test the existence of modifier loci influencing polycystic kidney disease (PKD) phenotypes, we derived a backcross between PKD susceptible Han:SPRD(cy/+) and control Brown Norway (BN) rats, and performed a whole-genome scan in 182 PKD affected hybrids showing different grades of disease severity. The genetic dissection of PKD in the cross allowed us to detect a modifier locus, Modpkdr1, on rat chromosome 8 that controls PKD severity, kidney mass and plasma urea concentration. Results from database searches and computational analyses demonstrated that the Modpkdr1 locus shows strong evidence of synteny conservation with human and mouse chromosomal regions controlling kidney diseases, including disease progression of Alport syndrome. Comparative genome mapping also provided an inventory of potential candidate genes for modifier(s) of PKD. Analyses of the coding regions for four strong candidates (Ctsh, Bcl2a1, Trpc1 and Slc21a2) in (cy/+), BN and Lewis rat strains did not reveal sequence variants that could be associated with PKD. The characterization of Modpkdr1 may provide new insights into modulating mechanisms involved in the pathogenesis of PKD that could delay disease progression in humans. It may also have strong implications in the identification of pathophysiological factors common to different renal disorders.

Entities:  

Mesh:

Year:  2002        PMID: 12189169     DOI: 10.1093/hmg/11.18.2165

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

1.  Role of genetic modifiers in an orthologous rat model of ARPKD.

Authors:  Caitlin C O'Meara; Matthew Hoffman; William E Sweeney; Shirng-Wern Tsaih; Bing Xiao; Howard J Jacob; Ellis D Avner; Carol Moreno
Journal:  Physiol Genomics       Date:  2012-06-05       Impact factor: 3.107

2.  Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.

Authors:  Susanne N E Boehn; Sonja Spahn; Sabine Neudecker; Andrea Keppler; Marie-Thérèse Bihoreau; Bettina Kränzlin; Priyanka Pandey; Sigrid C Hoffmann; Li Li; Vicente E Torres; Hermann-Josef Gröne; Norbert Gretz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

3.  A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse.

Authors:  Zongyu Zheng; Kai M Schmidt-Ott; Streamson Chua; Kirk A Foster; Rachelle Z Frankel; Paul Pavlidis; Jonathan Barasch; Vivette D D'Agati; Ali G Gharavi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

4.  Cyst formation in the PKD2 (1-703) transgenic rat precedes deregulation of proliferation-related pathways.

Authors:  Panayiota Koupepidou; Kyriacos N Felekkis; Bettina Kränzlin; Carsten Sticht; Norbert Gretz; Constantinos Deltas
Journal:  BMC Nephrol       Date:  2010-09-02       Impact factor: 2.388

5.  Genetic background of nonmutant Piebald-Virol-Glaxo rats does not influence nephronophthisis phenotypes.

Authors:  Jada Pasquale Yengkopiong; Joseph Daniel Wani Lako
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-02-18

6.  Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease.

Authors:  Priyanka Pandey; Benedikt Brors; Prashant K Srivastava; Andrea Bott; Susanne N E Boehn; Herrmann-Josef Groene; Norbert Gretz
Journal:  BMC Genomics       Date:  2008-12-23       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.